Review





Similar Products

mab c225  (ATCC)
96
ATCC mab c225
Mab C225, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/us12630559-246-9-11?v=ATCC
Average 96 stars, based on 1 article reviews
mab c225 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
anti hbs  (Abbott Laboratories)
86
Abbott Laboratories anti hbs
Anti Hbs, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pm42312388-10481-17-20?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
anti hbs - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
alinity i anti hbs reagent kit  (Abbott Laboratories)
86
Abbott Laboratories alinity i anti hbs reagent kit
Alinity I Anti Hbs Reagent Kit, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pmc13196985-170-37-42?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
alinity i anti hbs reagent kit - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
monoclonal antibody against flavivirus e protein  (ATCC)
96
ATCC monoclonal antibody against flavivirus e protein
Monoclonal Antibody Against Flavivirus E Protein, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/us12630589-562-14-21?v=ATCC
Average 96 stars, based on 1 article reviews
monoclonal antibody against flavivirus e protein - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
anti m1 antibody  (ATCC)
94
ATCC anti m1 antibody
Anti M1 Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pm42126187-97-5-7?v=ATCC
Average 94 stars, based on 1 article reviews
anti m1 antibody - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
anti hbs titers  (Abbott Laboratories)
86
Abbott Laboratories anti hbs titers
<t>Infant</t> <t>anti-HBs</t> titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).
Anti Hbs Titers, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pmc12968416-103-0-19?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
anti hbs titers - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
for anti hbs hbeag anti hbe anti hbc  (Abbott Laboratories)
86
Abbott Laboratories for anti hbs hbeag anti hbe anti hbc
<t>Infant</t> <t>anti-HBs</t> titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).
For Anti Hbs Hbeag Anti Hbe Anti Hbc, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pm42063539-315-59-64?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
for anti hbs hbeag anti hbe anti hbc - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
anti fcγ r monoclonal antibody  (ATCC)
96
ATCC anti fcγ r monoclonal antibody
<t>Infant</t> <t>anti-HBs</t> titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).
Anti Fcγ R Monoclonal Antibody, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pmc13161039-62-6-11?v=ATCC
Average 96 stars, based on 1 article reviews
anti fcγ r monoclonal antibody - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
architect anti hbs  (Abbott Laboratories)
86
Abbott Laboratories architect anti hbs
<t>Infant</t> <t>anti-HBs</t> titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).
Architect Anti Hbs, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/pm42033167-66-9-17?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
architect anti hbs - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
mab 225  (ATCC)
96
ATCC mab 225
<t>Infant</t> <t>anti-HBs</t> titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).
Mab 225, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+hbs+antibody/us12606633-776-19-21?v=ATCC
Average 96 stars, based on 1 article reviews
mab 225 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

Image Search Results


Infant anti-HBs titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).

Journal: The Journal of Allergy and Clinical Immunology: Global

Article Title: A randomized prospective study of neonatal hepatitis B vaccine immunogenicity in The Gambia and Papua New Guinea

doi: 10.1016/j.jacig.2026.100653

Figure Lengend Snippet: Infant anti-HBs titer response across vaccine and day randomization groups. Kruskal-Wallis rank-sum and Wilcoxon pairwise comparison significance markers indicating differences in anti-HBs titers assessed in ( A ) Gambian and ( B ) PNG infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) (ns = not significant, ∗<.05). The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. Kruskal-Wallis and Wilcoxon pairwise comparison P values indicating ( C ) differences in DOL30 anti-HBs titer response based on timing of catch-up vaccination at V2 in Gambian infants stratified by vaccine groups (HBV, BCG, HBV + BCG) and ( D ) differences in DOL30 anti-HBs titer response based on vaccine groups (HBV, BCG, HBV + BCG) in Gambian infants stratified by V2 catch-up vaccination time points. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers. E, Kruskal-Wallis rank-sum significance markers comparing mean anti-HBs titers assessed in infants across vaccine groups (HBV, BCG, HBV + BCG, delayed) at each time point (DOL0, DOL30, DOL128) in Gambian and PNG infants with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0 who had paired samples across all time points (GAM n = 441; PNG n = 52). Mean log 10 anti-HBs titers and SE bars are shown for each vaccine group at each time point. The delayed vaccine group was only followed to DOL30 and DOL128 time points in PNG infants. This analysis was performed on maternal-infant pairs. The dotted horizontal line represents the CoP (10 mIU/mL) for anti-HBs titers (ns = not significant, ∗<.05).

Article Snippet: Anti-HBs titers were measured at the Centre for Vaccinology, Ghent University, Belgium, using the Architect (or equivalent Alinity) analyzer (Abbott Laboratories; Chicago, Ill) following manufacturer’s instructions (kit ref: 7C18).

Techniques: Comparison

Relationship of maternal and infant plasma anti-HBs titers. A, Pearson correlation of anti-HBs titers (mIU/mL) assessed in maternal plasma following delivery and in neonatal plasma following birth at DOL0 among GAM (n = 589) and PNG (n = 52) maternal-infant paired samples. B, Univariate linear regression results predicting anti-HBs titers assessed in infants at DOL30 based on anti-HBs titers assessed in infants at DOL0. C, Univariate linear regression results predicting anti-HBs titers assessed in infants at DOL128 based on anti-HBs titers assessed in infants at DOL0. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0.

Journal: The Journal of Allergy and Clinical Immunology: Global

Article Title: A randomized prospective study of neonatal hepatitis B vaccine immunogenicity in The Gambia and Papua New Guinea

doi: 10.1016/j.jacig.2026.100653

Figure Lengend Snippet: Relationship of maternal and infant plasma anti-HBs titers. A, Pearson correlation of anti-HBs titers (mIU/mL) assessed in maternal plasma following delivery and in neonatal plasma following birth at DOL0 among GAM (n = 589) and PNG (n = 52) maternal-infant paired samples. B, Univariate linear regression results predicting anti-HBs titers assessed in infants at DOL30 based on anti-HBs titers assessed in infants at DOL0. C, Univariate linear regression results predicting anti-HBs titers assessed in infants at DOL128 based on anti-HBs titers assessed in infants at DOL0. These analyses were performed on maternal-infant pairs with concordant detectable (≥2.5 mIU/mL) and nondetectable (<2.5 mIU/mL) anti-HBs titers at DOL0.

Article Snippet: Anti-HBs titers were measured at the Centre for Vaccinology, Ghent University, Belgium, using the Architect (or equivalent Alinity) analyzer (Abbott Laboratories; Chicago, Ill) following manufacturer’s instructions (kit ref: 7C18).

Techniques: Clinical Proteomics